

Table of Contents

Preface	v
1 Plenary Articles.....	1
1.1 Proteomics strategies targeting biomarkers for cardiovascular disease..... <i>Arjen Scholten and Albert J.R. Heck</i>	3
1.2 Influence of pre-examination aspects on result's validity – are ISO 15189 requirements sufficient and clear? <i>Luděk Šprongl</i>	9
1.3 Posttranslational modifications in tumor diagnosis <i>Peter Nollau and Christoph Wagener</i>	12
1.4 Chronic inflammatory disease: a result of complex gene-environment interaction <i>Harald Renz, Petra Ina Pfefferle and Holger Garn</i>	16
2 Symposium Articles	21
2.1 Component-array technology diagnostics: a step forward in the study of the sensitization profile of allergic patients <i>Juan Manuel Acedo Sanz</i>	23
2.2 Pediatric metabolic syndrome: pathophysiology and molecular mechanisms..... <i>Julie Chemin and Khosrow Adeli</i>	26
2.3 Urinary 8-hydroxydeoxyguanosine as a biomarker of microangiopathic complications in type 2 diabetic patients..... <i>Amr Fattouh, Nermine H. Mahmoud, Shereen H. Atef and Abd El Rahman Gaber</i>	30
2.4 Biological variation data: the need for appraisal of the evidence base..... <i>William A. Bartlett</i>	35
2.5 RecoveryELISA – a newly developed immunoassay for measurement of therapeutic antibodies and the target antigen during antibody therapy <i>Pavel Strohner, Dieter Sarrach, Jens G. Reich, Antonia Staatz, Astrid Schäfer, Jens-Oliver Steiß, Thomas Häupl and Gunther Becher</i>	38
2.6 Genotypic prediction of HIV-1 tropism from plasma and peripheral blood mononuclear cells in the clinical routine laboratory <i>Christian Paar, Maria Geit, Herbert Stekel and Jörg Berg</i>	42
2.7 Expression of a subset of microRNAs in clinically non-functioning pituitary adenomas correlates with tumor size <i>Henriett Butz, István Likó, Sándor Czirják, Péter Igaz, Márta Korbonits, Károly Rác and Attila Patócs</i>	46

2.8	Serological markers of gastric pathology	50
	<i>Alberta Caleffi</i>	
2.9	BNP as a biomarker of cardiac impairment in neonates with congenital heart diseases	54
	<i>Massimiliano Cantinotti, Bruno Murzi, Simona Storti and Aldo Clerico</i>	
2.10	Are 25-hydroxyvitamin D assays fit for purpose?	58
	<i>Graham D. Carter</i>	
2.11	Update on multiple sclerosis.....	61
	<i>Anne H. Cross</i>	
2.12	Microalbuminuria and urinary retinol binding protein as markers of subtle renal injury in visceral leishmaniasis: sensitivity, specificity and predictive values of the immunoturbidimetric technique.	65
	<i>Nuha A.A. Elnojomi, Ahmed M. Musa, Brima M. Younis, Mohammed E. Elfaki, Ahmed M. El-Hassan and Eltahir A. Khalil</i>	
2.13	Occult hepatitis B virus infection: diagnosis and significance.....	68
	<i>Wolfram Hubert Gerlich, Christian Gisbert Schüttler and Dieter Glebe</i>	
2.14	Unmet needs in chronic kidney disease testing	72
	<i>Graham Jones</i>	
2.15	Towards a national chronic kidney disease testing program.....	75
	<i>Graham Jones</i>	
2.16	Biochemistry and metabolism of vitamin D.....	78
	<i>Glenville Jones</i>	
2.17	Diagnostics of thalassemia	82
	<i>Martha Kaeslin, Saskia Brunner-Agten and Andreas R. Huber</i>	
2.18	The specific roles of assessors during accreditation	85
	<i>Wim Huisman</i>	
2.19	Laboratory diagnosis of hereditary spherocytosis.....	88
	<i>May-Jean King</i>	
2.20	Quantification of blood folate forms using stable-isotope dilution ultra performance liquid chromatography tandem mass spectrometry	91
	<i>Susanne H. Kirsch, Wolfgang Herrmann and Rima Obeid</i>	
2.21	Evaluation of the new Marburg cerebrospinal fluid model with human spondylopathies	95
	<i>Tilman Otto Kleine, Christa Löwer, Siegfried Bien, Reinhardt Lehmitz and Alexandra Dorn-Beineke</i>	
2.22	E-learning experiences of national societies of clinical chemistry and laboratory medicine	99
	<i>Petr Kocna</i>	
2.23	The experience of Médecins Sans Frontières in laboratory medicine in resource-limited settings	102
	<i>Cara S. Kosack</i>	

2.24	Screening, identifying, and quantifying small molecules by hyphenated mass spectrometry in toxicology and drug monitoring – an update.....	108
	<i>Hans H. Maurer</i>	
2.25	Analytical quality in the Latin America area.....	111
	<i>Gabriel Alejandro Migliarino</i>	
2.26	Standardization in molecular diagnostics: definitions and uses of nucleic acid reference materials.....	116
	<i>Deborah A. Payne, François Rousseau, Cyril D.S. Mamotte, David Gancberg, Ron H.N. van Schaik, Heinz Schimmel and Mario Pazzagli</i>	
2.27	Profiling of antiphospholipid antibodies – association with cerebrovascular events in APS.....	120
	<i>Dirk Roggenbuck</i>	
2.28	Plasma levels of soluble CD30 and CD40L in pediatric patients after liver transplantation	124
	<i>Olga P. Shevchenko, Olga M. Tsurulnikova, Olga E. Gichkun, Rivada M. Kurabekova, Aleksandr A. Ammosov and Sergey V. Gautier</i>	
2.29	Diagnostic and prognostic value of presepsin (soluble CD14 subtype) in emergency patients with early sepsis using the new assay PATHFAST presepsin.....	128
	<i>Eberhard Spanuth, Henning Ebel, Boris Ivandic and Karl Werdan</i>	
2.30	Diagnostic workup of primary aldosteronism.....	134
	<i>Michael Stowasser</i>	
2.31	What should the clinical laboratory and the toxicologist-pharmacologist offer the poisoned patient?	138
	<i>Donald R.A. Uges</i>	
2.32	Novel aspects of von Willebrand factor – platelet glycoprotein IB interaction and signaling.....	142
	<i>Ulrich Walter, Stepan Gambaryan, Sabine Herterich and Suzanne M. Lohmann</i>	
2.33	Medical emergencies: what is the laboratory's role?	143
	<i>Donald S. Young</i>	